Thomas Evers

Integrated Evidence Generation Lead, Bayer Pharmaceuticals

Cologne Bonn Region

About

I am a highly motivated team player with 20+ years experience in the healthcare sector covering statistics/biometry, HEOR and RWE generation with demonstrated history of strategic and tactical business achievements in various roles at global and local level across different therapeutic areas. Work experience in the US, Belgium and Germany. Successful track record in stakeholder engagement with a focus on digital innovation and real world insights generation including the US market. I am committed to ensure patient access to innovation in an ethical manner whilst acknowledging the impact on the wider business.

Experience

  • Bayer Pharmaceuticals (24 yrs 2 mos)
    • Integrated Evidence Generation Lead, Thrombosis Portfolio & Cardiomyopathy
      May 2023 - Present · 3 yrs 2 mos

      Lead development of cross-functional, integrated evidence generation strategy and plan for Thrombosis Franchise to - maximize portfolio value - optimize launch & RoI - accelerate development, access & adoption - apply RWE / AI-based innovation - shape RWE acceptability

    • Integrated Evidence Generation Lead, Heart Failure Portfolio
      Apr 2021 - Apr 2023 · 2 yrs 1 mo

      Lead development of cross-functional, integrated evidence generation strategy and plan for Heart Failure Franchise to - maximize portfolio value - optimize launch & RoI - accelerate development, access & adoption - shape RWE acceptability

    • Director Global Market Access - Head Real World Insights early CV, Thrombosis, Cardio-Renal
      Jan 2017 - Apr 2021 · 4 yrs 4 mos

      - Global Market Access - Director - Head Real World Insights early CV, Thrombosis, Cardio-Renal - Lead Real-Life Evidence (RLE) Excellence, Precision Medicine, Digital, AI, Innovation, study simulation - Ensure RWE-related Market Access requirements are considered throughout all development stages across therapeutic areas (early CV, Thrombosis, Cardio-Renal) - Responsible for defining therapeutic area RWE strategy, identification of evidence gaps and coordination of tactics to optimise positioning, value, pricing and reimbursement - Identification of innovative stakeholder collaboration models / RWE-focussed methodologies and assessment of respective HTA / Payer acceptability (e.g. virtual arm, surrogate endpoint, cross-design synthesis) - Development of concepts related to digital business models - HEOR representative in global decision making bodies

  • Statistician, Health Economist at Universität zu Köln
    Oct 1998 - Apr 2002 · 3 yrs 7 mos

  • Head Health Economics, Statistician at ClinResearch / Institute for Numerical Statistics
    Aug 1996 - Sep 1998 · 2 yrs 2 mos